USANA Health Sciences, Inc. (NYSE:USNA - Get Free Report)'s stock price reached a new 52-week low during trading on Friday . The company traded as low as $25.26 and last traded at $25.53, with a volume of 187683 shares trading hands. The stock had previously closed at $27.15.
Analyst Ratings Changes
A number of equities research analysts recently weighed in on the company. DA Davidson dropped their price target on USANA Health Sciences from $38.00 to $36.00 and set a "neutral" rating for the company in a report on Thursday, February 27th. Sidoti downgraded shares of USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, February 18th. Finally, StockNews.com cut shares of USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a research note on Friday, February 14th.
Get Our Latest Stock Report on USANA Health Sciences
USANA Health Sciences Stock Down 0.0 %
The stock has a market cap of $457.54 million, a price-to-earnings ratio of 8.54, a PEG ratio of 0.93 and a beta of 1.00. The stock's fifty day moving average is $29.77 and its 200-day moving average is $34.34.
USANA Health Sciences (NYSE:USNA - Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.49 by $0.15. The firm had revenue of $213.61 million for the quarter, compared to analyst estimates of $208.82 million. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. As a group, equities research analysts predict that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current fiscal year.
Insider Activity
In other USANA Health Sciences news, insider Joshua Foukas sold 5,732 shares of the stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $32.54, for a total value of $186,519.28. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Jim Brown sold 5,000 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $29.47, for a total value of $147,350.00. Following the sale, the chief executive officer now owns 15,716 shares of the company's stock, valued at approximately $463,150.52. This represents a 24.14 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 15,920 shares of company stock valued at $500,285. 0.33% of the stock is owned by company insiders.
Institutional Trading of USANA Health Sciences
Several institutional investors have recently added to or reduced their stakes in USNA. R Squared Ltd bought a new stake in shares of USANA Health Sciences in the fourth quarter valued at about $28,000. Versant Capital Management Inc raised its stake in USANA Health Sciences by 542.5% in the 1st quarter. Versant Capital Management Inc now owns 1,150 shares of the company's stock worth $31,000 after purchasing an additional 971 shares in the last quarter. Parallel Advisors LLC boosted its holdings in USANA Health Sciences by 8,141.2% in the 1st quarter. Parallel Advisors LLC now owns 1,401 shares of the company's stock valued at $38,000 after purchasing an additional 1,384 shares during the period. KLP Kapitalforvaltning AS acquired a new position in shares of USANA Health Sciences during the 4th quarter worth approximately $83,000. Finally, Quantbot Technologies LP bought a new position in shares of USANA Health Sciences during the fourth quarter worth approximately $132,000. 54.25% of the stock is currently owned by institutional investors.
About USANA Health Sciences
(
Get Free Report)
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.
Featured Stories
Before you consider USANA Health Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and USANA Health Sciences wasn't on the list.
While USANA Health Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
